The field of prostate cancer research has been greatly hindered by the paucity of new investigators entering nto the field. In recognition of the need to help establish independently funded investigators in the field of translational prostate cancer research, the UMCCC Prostate SPORE has supported two to three junior acuity per year. The focus of the Career Development Program is to give investigators the ability to generate data that will become the preliminary data for prostate cancer R01 grant applications. The SPORE currently commits $70,000 annually per investigator. Career Development awardees are currently funded for a maximum of two years, subject to annual review. Individual departments supply another $10,000 per year in matching funds. Investigators, many of whom are outside the field of prostate cancer, meet quarterly with Drs. Wood and Macoska who act as clinical and basic science resource mentors, respectively. Dr. David Wood is a Professor in the Department of Urology with a subspecialty in urologic oncology and serves as the 'clinical"""""""" mentor for the Career Development Program. Dr. Wood is nationally and internationally recognized for his expertise in urologic oncology, particularly prostate cancer. Dr. Macoska is a Professor of Urology, and Director of the cDNA Microarray Core of the UMCCC. Dr. Macoska is the """"""""basic science"""""""" resource mentor for the career development program. Both Drs. Wood and Macoska are very experienced .in the training of clinical and basic science fellows and faculty. The progress of the Career Development investigators is monitored yearly by presentation to the Operating Committee and funding can be stopped if the investigators are not fulfilling their commitment to prostate cancer translational research. During the current period, CDP investigators have generated $991,000 in new grant monies and produced 27 manuscripts. Since 1995, our CDP has invested $2.3 million in the program and supported 15 investigators. In addition, since 1995, the CDP investigators have generated an impressive $11.6 million in subsequent grants anc produced 72 manuscripts. The effectiveness of this program is reflected by the fact that three career development investigators (Drs. Cooney, Chinnaiyan, and Loberg) have become full project investigators on the SPORE during this time.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Wang, Xiaoju; Qiao, Yuanyuan; Asangani, Irfan A et al. (2017) Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell 31:532-548.e7
Blattner, Mirjam; Liu, Deli; Robinson, Brian D et al. (2017) SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell 31:436-451
Dai, Xiangpeng; Gan, Wenjian; Li, Xiaoning et al. (2017) Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med 23:1063-1071
Zheng, Yi; Sun, Yubing; Yu, Xinwei et al. (2016) Angiogenesis in Liquid Tumors: An In Vitro Assay for Leukemic-Cell-Induced Bone Marrow Angiogenesis. Adv Healthc Mater 5:1014-24
Roychowdhury, Sameek; Chinnaiyan, Arul M (2016) Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin 66:75-88
Lange, Ethan M; Ribado, Jessica V; Zuhlke, Kimberly A et al. (2016) Assessing the Cumulative Contribution of New and Established Common Genetic Risk Factors to Early-Onset Prostate Cancer. Cancer Epidemiol Biomarkers Prev 25:766-72
Hu, Shuhuan; Liu, Guangyu; Chen, Weiqiang et al. (2016) Multiparametric Biomechanical and Biochemical Phenotypic Profiling of Single Cancer Cells Using an Elasticity Microcytometer. Small 12:2300-11
Chen, Weiqiang; Allen, Steven G; Reka, Ajaya Kumar et al. (2016) Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics. BMC Cancer 16:614
Van Allen, Eliezer M; Robinson, Dan; Morrissey, Colm et al. (2016) A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget 7:52888-52899
Mehra, Rohit; Udager, Aaron M; Ahearn, Thomas U et al. (2016) Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. Eur Urol 70:549-552

Showing the most recent 10 out of 522 publications